v3.26.1
SCHEDULE OF SEGMENT INFORMATION (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Product Information [Line Items]        
Total net revenue $ 1,510,579 $ 1,269,483 $ 2,862,106 $ 3,123,080
Total operating loss (3,334,864) (2,515,560) (6,951,840) (5,142,699)
Non-operating (expense), net (31,218) (1,516,243) (44,852) (1,540,826)
Net loss before income tax expense (3,366,082) (4,031,803) (6,996,692) (6,683,525)
Income tax expense (28,984) (37,679)
Net loss (3,366,082) (4,060,787) (6,996,692) (6,721,204)
Diagnostic R&D [Member]        
Product Information [Line Items]        
Total net revenue 1,131
Total operating loss (837,460) (440,651) (1,521,207) (946,390)
Laboratory Services [Member]        
Product Information [Line Items]        
Total net revenue [1] 1,510,579 1,269,483 2,860,975 3,123,080
Total operating loss (1,787,865) (1,646,471) (3,620,457) (3,914,127)
General Corporate Activities [Member]        
Product Information [Line Items]        
Total operating loss $ (2,220,118) $ (1,697,921) $ (4,672,282) $ (3,405,262)
[1] The majority of the decrease versus the prior year is primarily due to discontinuing certain unprofitable pathology services to focus on CyPath® Lung and other high-margin services.